



(51) International Patent Classification:

A61K 48/00 (2006.01)

(21) International Application Number:

PCT/US2024/036954

(22) International Filing Date:

05 July 2024 (05.07.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/512,546 07 July 2023 (07.07.2023) US
63/616,045 29 December 2023 (29.12.2023) US

(71) Applicant: **KRIYA THERAPEUTICS, INC.** [US/US];
4105 Hopson Road, Morrisville, NC 27560 (US).

(72) Inventors: **STONE, Michele**; c/o Kriya Therapeutics, Inc.,
4105 Hopson Road, Morrisville, NC 27560 (US). **CEPE-
DA, Diana**; c/o Kriya Therapeutics, Inc., 4105 Hopson
Road, Morrisville, NC 27560 (US). **CASTELLANOS,
Ruth**; c/o Kriya Therapeutics, Inc., 4105 Hopson Road,
Morrisville, NC 27560 (US). **ENGLES, Michael**; c/o Kriya
Therapeutics, Inc., 4105 Hopson Road, Morrisville, NC
27560 (US). **RAMASWAMY, Shankar**; c/o Kriya Ther-
apeutics, Inc., 4105 Hopson Road, Morrisville, NC 27560
(US). **MURPHY, Andrew**; c/o Kriya Therapeutics, Inc.,
4105 Hopson Road, Morrisville, NC 27560 (US). **ECLOV,
Rachel**; c/o Kriya Therapeutics, Inc., 4105 Hopson Road,
Morrisville, NC 27560 (US).

(74) Agent: **NANNENGA-COMBS, Bonnie, W.** et al.; Sterne,
Kessler, Goldstein & Fox P.L.L.C., 1101 K Street N.W., 10th
Floor, Washington, DC 20005 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: PERIOULAR DELIVERY OF AAV VECTORS FOR TREATING OPHTHALMIC PATHOLOGIES

(57) Abstract: Provided herein is a method of delivering a pharmaceutical composition comprising an AAV vector to an ocular or periocular tissue, comprising injecting the AAV vector periocularly (e.g., periocular injection, optionally peribulbar injection). In some aspects, the method is for use in treating an ophthalmic pathology (e.g., thyroid eye disease (TED) in a subject in need thereof.

